^
    Back
    Association details:
    Biomarker:MET overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug:erlotinib (EGFR inhibitor) +
    tivantinib (ARQ 197) (c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Medicine (Baltimore)
    Title:

    Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non-small-cell lung cancer: A meta-analysis based on randomized controlled trials

    Published date:
    06/19/2020
    Excerpt:
    ET appears to be superior to EP due to better PFS and higher response rates, especially for patients with high MET expression and good VeriStrat.
    DOI:
    10.1097/MD.0000000000020596